Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-label Phase 1/2 Study of TYRA300 in Advanced Urothelial Carcinoma and Other Solid Tumors With Activating FGFR3 Gene Alterations (SURF301)

Next Previous
X
Search
Trial Profile

A Multicenter, Open-label Phase 1/2 Study of TYRA300 in Advanced Urothelial Carcinoma and Other Solid Tumors With Activating FGFR3 Gene Alterations (SURF301)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TYRA-300 (Primary)
  • Indications Bladder cancer; Carcinoma; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Acronyms SURF301
  • Sponsors Tyra Biosciences

    • Most Recent Events

    • 10 Dec 2024 According to an abstract published 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics, Phase 2 will enroll participants in FGFR3+ mUC and other tumor types to further explore the anti-tumor activity and safety of TYRA-300
    • 10 Dec 2024 Trial design is discussed in an abstract published 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics
    • 07 Nov 2024 According to a Tyra Biosciences media release, company plans to expand the clinical development of TYRA-300 into NMIBC to address the unmet needs in this cancer population with an efficacious, orally available therapy. TYRA remains on track to submit an Investigational New Drug (IND) application for a Phase 2 study of TYRA-300 in NMIBC before year-end 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top